• Home
    • Leucémie myéloïde chronique
    • Leucemia Mieloide Crónica
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • Other CML experts in America >
      • Other CML experts in Canada >
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Luigina Mollica
        • Dr. Dennis Kim
        • Dr. Pierre Laneuville
        • Dr. Conrad Vincent Fernandez
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Mark Hnatiuk
      • Other CML experts in US >
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • Rey Garcia, RN, BSN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Javier Pinilla-Ibarz
        • Dr. Catriona Jamieson
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Franziska Michor
        • Dr. Frank Giles
        • Dr. Gabriella Hobbs
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Matt Kalaycio
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Ellen K. Ritchie
        • Dr. Karen Seiter
        • Dr. Kendra Sweet
        • Dr. Neil Shah
        • Dr. Richard T Silver
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Sangmin Lee
        • Dr. Bin Zhang
      • Other CML experts in South America >
        • Dr. Michele Bianchini
        • Dra Beatriz Moiraghi
        • Dra. Carla Boquimpani
        • Dr Carolina Pavlovsky
    • Other CML Experts in Europe >
      • CML Expert in Belgium >
        • Pr Gregor Verhoef
      • CML expert in France >
        • Dr. François-Xavier Mahon
        • Dr Aude Charbonnier
        • Dr. Delphine Rea
        • Dr. Gabriel Etienne
        • Dr. Lawrence Legros
        • Dr. Marie-Joëlle Mozziconacci
        • Pr. Mauricette Michallet
        • Dr. François Guilhot
        • Dr Françoise Huguet
        • Dr. Stéphane Prost
        • Dr. Philippe Rousselot
        • Dr. Eliane Gluckman
        • Dr. Franck-Emmanuel Nicolini
      • CML expert in Italy >
        • Dr. Chiara Elena
        • Dr. Michele Baccarani
        • Dr. Giuseppe Saglio
      • CML expert in UK >
        • Dr. Jane Apperley
        • Dr. Stephen O'Brien
        • Dr. Georgios Nteliopoulos
        • Dr. Adam Mead
        • Dr. Tessa L Holyoake
      • CML expert in Germany >
        • Dr. Andreas Hochhaus
        • Dr Susanne Saussele
        • Dr. Martin Müller
      • CML expert in Portugal >
        • Dr. Antônio Medina de Almeida
      • CML expert in Spain >
        • Dr. Juan Luis Steegmann
      • CML expert in Netherlands >
        • Dr. Jeroen J.W.M. Janssen
      • CML expert in Sweden >
        • Dr. Johan Richter
      • CML expert in Czech Republic >
        • Dr. Hana Klamova
    • Other CML experts in Asia >
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Uday Yanamandra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • Other CML experts in Africa >
      • Dr. Anthony Oyekunle
    • Other CML experts in Australia >
      • Dr. Ilaria Pagani
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. David T. Yeung
      • Dr. Liu Lu
      • Dr. Naranie Shanmuganathan
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML >
      • Precision medicine in chronic myeloid leukemia
      • Philadelphia chromosome
      • BCR-ABL Transcripts
      • Sokal, Hasford, and EUTOS scores
    • General concepts >
      • Blood
      • Bone Marrow
      • DNA
      • Stem Cells
      • Immune System >
        • Natural killer cell - NK
        • T Cells
      • Blood-Brain Barrier
    • Clinical Trials
    • Treatment response in CML
    • Resistance to treatment in CML >
      • Molecular monitoring in CML >
        • Polymerase Chain Reaction
        • Dr. Kary Bank Mullis
      • Non-adherence of CML patients
      • Sensitive detection of BCR-ABL1 mutations
      • JAK2 Gene
    • Donor lymphocyte infusion (DLI)
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Imatinib
    • Tasigna (Nilotinib) >
      • Generic nilotinib
    • Sprycel (Dasatinib) >
      • Generic Dasatinib
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • ABL001 (Asciminib)
    • Synribo (Omacetaxine )
    • Jakafi (Ruxolitinib)
    • Flumatinib
    • (Bafetinib)
    • (Danusertib)
    • (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • BP1001
    • HQP1351 (Olverembatinib)
    • K0706
    • ​ S116836
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Peripheral Neuropathy in CML
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Food and Drug Interactions
    • Living with CML and diabetes
    • CML and comorbidities
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Music therapy >
        • YouTube creation by CMLer's family
        • Relaxing Music for Stress Relief. Calm Music for Meditation, Sleep, Healing Therapy, Spa
        • Debussy – Relaxing music - Clair de lune et autres...
        • Delicate music for the soul and LIFE, and birdsong soothes the nervous system.
        • Adagio for Strings (Samuel Barber)
        • Amélie Soundtrack ♥ Comptine d'Un Autre Été
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • 30 years and plus survivors >
      • Mark Popadick
      • Mary Sullivan
      • Tom Strodl
      • Dr. Robert Patenaude -E
      • Skip Duffe
    • 20 years and plus survivors >
      • Doug Jenson
      • Joannie Clements
      • Mel Mann
      • Kevin Williams
      • Rich Jones
      • Tanja Fajon
      • Tamera Simonson
      • Virginia Garner
    • 10 years and plus survivors >
      • Jan Geissler
      • Mary Jane Bertram
      • Pat Elliott
      • Tegan Kubler
      • Jo'story
      • Rob Shick
      • Gary Gonzales
      • Hans Loland
      • Drew Johnston
      • Erin Havel (Author)
      • Sohag
      • Erin Zammett Ruddy
      • Kayla Naton (Pregnancy)
      • Jean McGlynn
      • Tom Cleaver
    • New CMLers >
      • Skye Davidson
      • Amanda Steffy
      • Abbi Evans
      • Alyssa
      • Austin Granatowicz
      • Brown Dudley
      • Nigel
      • Katie
      • Kris
      • Ron Robbecke
    • Some celebrities >
      • How to get the password?
      • Alexa Score
      • Laura Boyd
      • Dr. Richard Rockefeller
      • Ryan O'Neal
      • Tim Holcomb
      • Doris Muramatsu
      • Charlie Schlatter
      • Kareem Abdul-Jabar
      • Kelvin Alston
      • Carlos Carrasco
      • Jason Blake
      • Brian Boyle
      • Roman Reigns
      • Rick Upchurch
    • Suzan Mc Namara and the petition
    • Bud Romine - the first patient
    • Other testimonials
    • Blogs >
      • Blog recently updated >
        • Access CML Drugs
        • Living with CML
        • Michelle D's Blog
        • Jon's Blog
        • Justin Ozuna's Blog
        • Trey's CML Leukemia Blog
      • Blog not recently updated >
        • CMKID's blog – Dislodging the bullet - 2012
        • CML Recovery - Stopping KTI -2011
        • Hans's Blog -2012
        • Elizabeth's Blog - my leukemia - 2013journey
        • Elizabeth's Blog - Heart of the rose -2011
        • Joe's Blog - 2012
        • Josh's Blog - 2014
        • Mannan's Blog -2014
        • Ian's Blog -2014
        • Matt's Blog - 2012
        • Matthew's Blog - 2014
        • Michelle's Blog -2012
        • Nayree's Blog -2011
        • Rob's Blog - 2011
  • Global News on CML
    • English - Latest CML News >
      • News -Archives 2019-2018
      • News - Archives 2017-2016
      • News Archives - 2015-2014
      • News-Archives -2013-2012
      • News - Archives 2011-2001
    • French (Français) - Dernières nouvelles
    • Spanish (Español)-Ultimas noticias
  • Links to other sites, forums and Facebook
    • Sites ( English and other languages)
    • Forums (English and other languages)
    • CML on Facebook (English and other languages)
    • CML on Twitter
    • Audio Podcast
  • Various topics
    • CML patients and the coronavirus
    • You’ve just been diagnosed
    • CML causes
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • Increased Risk of Secondary Cancers with CML
    • Vaccination of CMLers
    • CML and pregnancy
    • Children with CML
    • Elderly patients with CML
    • Bone marrow transplant
    • Stem cells from umbilical cord blood
    • CML Blast Crisis treatment
    • Mutation T315I
    • Sports with CML
    • History of CML
    • CML Awareness Day
    • The movie "Dying to Survive"
  • Cure possible for CML?
    • Hematopoietic stem cell transplantation using single UM171-expanded cord blood
    • Combination of tyrosine kinase inhibitor with other medication >
      • Combinaison of hydroxychloroquine with tyrosine kinase inhibitor
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
    • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
    • Inhibition of the protein Ezh2 can cure CML?
    • Inhibition of STAT5 in conjunction with standard TKI therapy
    • PROTAC-mediated Targeted Protein Degradation
    • CML vaccine
    • Can immunotherapy cure leukemia?
    • Could fasting cure chronic myeloid leukemia
    • Chimeric Antigen Receptor T-Cell Therapy
    • Can genetic sequencing help to cure leukemia?
    • Can the new drug CX-5461 cure leukemia?
    • CRISPR-Cas9 gene-editing technique
    • Presence of bcr abl fusion transcripts in healthy individua
    • Math could help cure leukemia
    • Natural Medicine >
      • Possible cure for CML in Fish Oil
      • Betel leaf may help fight CML
      • Feverfew extract (parthenolide)
      • Can dandelions kill cancer?
      • Can curcumin cure leukemia?
  • Treatment free remission(TFR)
    • The French trial called STIM (Stop Imatinib)
    • De-escalation of treatment
    • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
  • Educational videos
    • Educational videos (in English)
    • Educación de vídeos en español (in Spanish)
    • Vidéos pédagogiques en français (in French)
  • Educational events
  • CML Glossaries
  • Moral Support
    • Where to get help and support
    • Family support
    • Dances at the Cancer Research Centre
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • Stronger
    • The march toward healing
    • Be happy
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2020 - Chicago
      • ASCO 2019 - Chicago
      • ASCO 2018 - Chicago
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2020 - Virtual
      • ASH 2019- Orlando
      • ASH 2018 - San Diego
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG2019 - Fuzhou - China
      • BTG2018 - Seoul, Korea (South)
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2019 - Lisbon - Portugal
      • CML Horizon 2018 -Warsaw (Pologna)
      • CML Horizon 2017- Frankfurt (Germany)
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • EHA 2020 - Frankfurt,Germany(
      • EHA 2019 - Amsterdam (Netherlands)
      • EHA 2018 - Stockholm(Sweden)
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
    • ESH - European School of Haematology >
      • ESH 2020 - Mandelieu-La Napoule, -France
      • ESH 2019 - Bordeaux - France
      • ESH 2016 - Houston - USA
      • ESH 2015 - Estoril - Portugal
      • ESH 2014 - Philadelphia
  • Professionnel help and literature
    • Dr. Siddhartha Mukherjee
  • Patient Rights
  • New technological advances
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • Awards & Recognition
  • Private group registration
    • Membership registration - CMLeukemia private group
    • Enregistrement des membres - Groupe privé CMLeukemia
    • Registro de membresía - CMLeucemia grupo privado
  • DONATE
  • About us
    • Our mission
    • Total access on the website - membership
  • Contact us
Chronic Myeloid Leukemia

Sprycel (dasatinib)  -  CML  -   Chronic Myeloid Leukemia

''Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibband sold under the trade name Sprycel®. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitorapproved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastaticmelanoma.
The drug is named after one of the inventor chemists, 
Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.''
Extract of  Wikipedia
                                       
See also the List of side effects ​
SITES 
​

Sprycel®​
FORUMS    

CMLSupport (discussions about Sprycel
®)

CLINICAL TRIALS

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic‐Phase Chronic Myeloid Leukemia

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

                     All clinical trials with dasatinib
VIDEOS

What are the efficacy and safety considerations of dasatinib therapy?
April 29, 2016, MediCom Oncology

Sprycel
®(dasatinib) in the Second-Line Setting
February 17, 2015, OncLiveTV

Sprycel
®, a new medication for CML – Dr Lipton
March 28, 2007, For Your Life


 ARTICLES
​
A Case of Long-Term Dasatinib-Induced Proteinuria and Glomerular Injury
May 9, 2020, 
PubMed

Switch From Imatinib to Dasatinib May Benefit Certain Patients With CML-CP
May 7, 2020, 
Oncology Learning Network

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
April 7, 2020, 
PubMed

Long-term results of frontline dasatinib in chronic myeloid leukemia
February 6, 2020,  
MDlinx

Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group
January 1, 2020, PubMed


Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
November 26, 2019, Nature.com
​
The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up
November 13, 2019, ASH2019


Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
August 26, 2019, Dovepress


Dasatinib shows promise as a control agent for CAR T cells
July 5, 2019, MDedge


Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
September 2018, PubMed


The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia
August 12, 2018,  PubMed


Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
August 9, 2018, PubMed

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
August 2018, Springer Link

EC approves expanded indication for Sprycel
July 6, 2018, thepharmaletter

Dasatinib Approved in Europe for Pediatric Ph+ Chronic Phase CML
July 5, 2018,  OncLive

Maintenance therapy with dasatinib administrated every other day in patients with chronic myeloid leukemia
May 17, 2018, EHA 2018

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
May 3, 2018,  PubMed

Dasatinib: A Safe and Effective Option for Pediatric CML
March 5, 2018, Cancer Therapy Advisor

Dasatinib dose management for the treatment of chronic myeloid leukemia
January 25, 2018, Cancer

Pepsi® or Coke®? Influence of acid on dasatinib absorption
January 1, 2018, PublMed


Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)
December 2017, 
ASH 2017
​
 ​
Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
​
December 2017, 
ASH 2017
 
Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)

December 2017, ASH 2017

Interim Results of the Canadian Tyrosine Kinase Inhibitor
Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

December 2017, ASH 2017

Dasatinib increases endothelial permeability leading to pleural effusion
October 14, 2017, European Respiratory Journal


Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal

New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment
June 3, 2016, NCBI

Newer Generation TKIs May Be More Effective Than Imatinib for CP-CML
March 30, 2016 , Cancer Therapy Advisor

Dasatinib Commonly Induces Lymphocytosis in CML Patients
March 29, 2016, CancerNetwork

What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
February 2016, PublMed

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients
December 7, 2015, ASH 2015

Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias
December 7, 2015, ASH 2015

Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib
December 7, 2015, ASH 2015

Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
December 7, 2015, ASH 2015

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
December 5, 2015, ASH 2015

Bristol-Myers Leukemia Drug Sprycel®'s US Label Updated
August 14, 2015,  Yahoo News

FDA Approves Labeling Update to Include New Sprycel
® Data
August 13, 2015,  Cancer Therapy Advisor

An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML)  
June 2, 2014, 2014 ASCO Annual Meeting


Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study
February 14, 2014, Blood Journal


Efficacy and safety of dasatinib versus  imatinib in the East Asian subpopulation of the DASISION trial of newly  diagnosed chronic myeloid leukemia in chronic phase
December 2013, DocGuide.com

Dasatinib Shows  Promise for Pediatric CML, ALL  Patients
September 13, 2013, Cancer  Network

Impressive thrombocytosis evolving in a  patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional  JAK2V617F
September 5, 2013, Experimental Hematology &  Oncology


Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
April 2013, Research  Gate

Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
October 29, 2012,  PublMed

A trial of dasatinib and BMS-833923 for chronic myeloid  leukaemia (CA180323)
October 22, 2012,  Cancer Research  UK

Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
October 1, 2012, PublMed

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by  dasatinib.
September 15, 2012,  PublMed

Dasatinib Achieves Higher Response Rate Than Imatinib in CML
September 6, 2012, Cancer Network


Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first line dasatinib   
May 29, 2012, Journal Blood

Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives
January 15, 2012, PubLMed

Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells
December 19, 2011,
Nature

FDA Drug Safety Communication: Sprycel
® (dasatinib) and risk of pulmonary arterial hypertension                   **** WARNING ***
November 10, 2011, U.S. Food and Drug Administration


Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
July 1, 2011, European Respiratory Journal


Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011,  2011 ASCO Annual Meeting

Dasatinib Shows Superior Efficacy and Acceptable Tolerability, Supporting First-Line Use in Newly Diagnosed CML-CP
June 3 , 2011,  Monthly Prescribing Reference


FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
October 28, 2010, FierceBiotech

Dasatinib, an immodulator?
August 2010, Journal Blood


Pleural effusions due to dasatinib
July 16, 2010, PublMed


Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
December 2009, PubMed


Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia - Dasatinib is associated with increased risk of bleeding
July 9, 2009, Journal Blood

Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday

Dasatinib suppresses in vitro natural killer cell cytotoxicity
April 15, 2008, Journal Blood

Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
April 8, 2008, PublMed


Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine

Dasatinib effective in treating resistant CML cases
January 21, 2006,  The Pharmaceutical Journal



          (See our disclaimer - Voir notre avis de non-responsabilité- Vea nuestro descargo de responsabilidad)
​
        Privacy Policy   
                    
Copyright © 2010-2021 CMLeukemia.com
Protected by Copyscape     DMCA.com Protection Status